Market Newsdesk

December 23, 2025 4:46 pm

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

OVERLAND PARK, Kan., Dec. 23, 2025 (GLOBE NEWSWIRE) — Compass Minerals (NYSE: CMP), a leading global provider of essential minerals, today released the following notice:

A U.S. District Court authorized this Notice. This is not a solicitation from a lawyer.

TO:
ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF COMPASS MINERALS INTERNATIONAL, INC. (“COMPASS” OR THE “COMPANY”) COMMON STOCK AS OF OCTOBER 24, 2025.

PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE OF STOCKHOLDER DERIVATIVE LITIGATION AND CONTAINS IMPORTANT INFORMATION REGARDING YOUR RIGHTS.

IF THE COURT APPROVES THE SETTLEMENT OF THE DERIVATIVE ACTIONS, PLAINTIFFS’ RELEASING PARTIES WILL BE FOREVER BARRED FROM CONTESTING THE APPROVAL OF THE PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE, AND FROM PURSUING RELEASED CLAIMS.

THESE ACTIONS ARE NOT “CLASS ACTIONS.” THUS, THERE IS NO COMMON FUND UPON WHICH YOU CAN MAKE A CLAIM FOR A MONETARY PAYMENT.

PLEASE TAKE NOTICE that these actions are being settled on the terms set forth in a Stipulation and Agreement of Settlement dated October 24, 2025 (the “Stipulation”). The purpose of this Notice is to inform you of:

the existence of the above-captioned derivative actions pending in the United States District Court for the District of Kansas (the “Court”), captioned Morelli v. Crutchfield, et al., Lead Case No. 2:24-cv-02496-EFM-ADM (D. Kan.) and Assad v. Crutchfield, et al., Case No. 2:25-cv-02186-EFM-ADM (D. Kan.) (the “Actions”);
the proposed settlement between Plaintiffs and Defendants (together, “Parties”) reached in the Actions (the “Settlement”),
the hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement and dismissal of the Actions with prejudice,
Plaintiffs’ Counsel’s application to the Court for a Fee and Expense Amount to be paid by Compass’s insurers, and
Plaintiffs’ Counsel’s application to the Court for case Service Awards to the two Plaintiffs.

This Notice describes what steps you may take in relation to the Settlement. This Notice is not an expression of any opinion by the Court about the truth or merits of Plaintiffs’ claims or Defendants’ defenses. This Notice is solely to advise you of the proposed Settlement of the Actions and of your rights in connection with the proposed Settlement.

Summary

On October 24, 2025, Compass, in its capacity as a nominal defendant, entered into the Stipulation to resolve the Actions, which Stipulation was filed in the Court. The Actions were brought derivatively on behalf of Compass against certain current and former directors and officers of the Company. Compass was named as a nominal defendant in the Actions. The Stipulation, and the settlement contemplated therein (the “Settlement”), subject to the approval of the Court, are intended by the Parties to fully, finally, and forever compromise, resolve, discharge, and settle the Released Claims and to result in the complete dismissal of the Actions with prejudice, upon the terms and subject to the conditions set forth in the Stipulation. The proposed Settlement requires the Company to adopt and maintain certain corporate governance reforms and procedures, as outlined in Exhibit A to the Stipulation (the “Reforms”), subject to Court approval.

In recognition of the substantial benefits conferred upon Compass as a direct result of the Reforms achieved through the prosecution and Settlement of the Actions, the Parties agreed on September 12, 2025, that Compass’s insurers shall pay to Plaintiffs’ Counsel attorneys’ fees and expenses in the amount of eight hundred fifty thousand dollars ($850,000.00) (the “Fee and Expense Amount”), subject to Court approval. Plaintiffs’ Counsel shall also apply to the Court for service awards to be paid to the two Plaintiffs in an amount of up to one thousand five hundred dollars ($1,500.00) each (the “Service Awards”), to be paid out of the Fee and Expense Amount.

This notice is a summary only and does not describe all of the details of the Stipulation and its exhibits. For full details of the matters discussed in this summary, please see the full Stipulation and its exhibits posted on the Investor Relations portion of the Company’s website, https://‌investors.compassminerals.com/investors-relations/overview/default.aspx, contact Plaintiffs’ Counsel as set forth below, or inspect the full Stipulation and its exhibits filed with the Clerk of the Court.

What are the Lawsuits About?

The Actions are brought derivatively on behalf of nominal defendant Compass and allege that, inter alia, between February 8, 2023, and March 25, 2024, at least, the Individual Defendants breached their fiduciary duties by issuing and/or causing Compass to issue false and misleading statements and omissions and failing to disclose and/or causing the Company to fail to disclose to the investing public, among other things, that testing on the Company’s proprietary magnesium chloride-based aerial fire retardants did not confirm such fire retardants’ safety and, thus, overstating the prospects of the U.S. Forest Service awarding Compass a renewed contract for using its proprietary magnesium chloride-based aerial fire retardants for the 2024 fire season.

Why is there a Settlement of the Actions?

The Court has not decided in favor of Defendants or the Plaintiffs. Instead, the Parties agreed to the Settlement to avoid the distraction, costs, and risks of further litigation, and because the Parties agree, and the Company determined, that the Reforms that the Company will adopt, implement, and maintain as part of the Settlement provide substantial benefits to Compass and its stockholders.

Individual Defendants have denied and continue to deny each and all of the claims and contentions alleged by the Plaintiffs in the Actions. Individual Defendants have expressly denied and continue to deny all charges of wrongdoing or liability against them arising out of any of the conduct, statements, acts, or omissions alleged, or that could have been alleged, in the Actions. Nonetheless, Defendants have concluded that it is desirable for the Actions to be fully and finally settled in the matter and upon the terms and conditions set forth in this Stipulation.

The Settlement Hearing, and Your Right to Object to the Settlement

The Court entered an order preliminarily approving the Stipulation and the Settlement contemplated therein (the “Preliminary Approval Order”) and providing for notice of the Settlement to be provided to current Compass stockholders who owned Compass stock as of October 24, 2025 (“Current Compass Stockholders”). The Preliminary Approval Order further provides that the Court will hold a hearing (the “Settlement Hearing”) on February 20, 2026 at 1:00 p.m. before the Honorable Eric F. Melgren at the U.S. District Court for the District of Kansas, 401 N. Market, Wichita, Kansas 67202 to among other things: (i) determine whether the proposed Settlement is fair, reasonable and adequate and in the best interests of the Company and its stockholders; (ii) consider any objections to the Settlement submitted in accordance with this Notice; (iii) determine whether a judgment should be entered dismissing all claims in the Actions with prejudice, and releasing the Released Claims against the Released Persons; (iv) determine whether the Court should approve the agreed-to Fee and Expense Amount; (v) determine whether the Court should approve the Service Awards to the two Plaintiffs, which shall be funded from the Fee and Expense Amount; and (vii) consider any other matters that may properly be brought before the Court in connection with the Settlement. Upon final approval of the Settlement, the Actions will be dismissed with prejudice.

The Court may, in its discretion, change the date and/or time of the Settlement Hearing without further notice to you. If you intend to attend the Settlement Hearing, please consult the Court’s calendar or the Investor Relations portion of the Company’s website, https://investors.compassminerals.com/investors-relations/overview/default.aspx, for any change in the date, time, or format of the Settlement Hearing.

Any Current Compass Stockholder who wishes to object to the fairness, reasonableness, or adequacy of the Settlement as set forth in the Stipulation, or to the Fee and Expense Amount or Service Awards, may file with the Court a written objection. An objector must, at least twenty-one (21) days prior to the Settlement Hearing: (1) file with the Clerk of the Court and serve (either by hand delivery or by first-class mail) upon the below-listed counsel a written objection to the Settlement setting forth (i) a written notice of objection with the case names and numbers (Morelli v. Crutchfield, et al., Lead Case No. 2:24-cv-02496-EFM-ADM (D. Kan.); Assad v. Crutchfield, et al., Case No. 2:25-cv-02185-EFM-ADM (D. Kan.)); (ii) the Current Compass Stockholder’s name, legal address, and telephone number; (iii) notice of whether such Current Compass Stockholder intends to appear at the Settlement Hearing and the reasons such Current Compass Stockholder desires to appear and be heard, and whether such Current Compass Stockholder is represented by counsel and if so, contact information for counsel; (iv) competent evidence that such Current Compass Stockholder held shares of Compass common stock as of the date of the Stipulation and continues to hold such stock as of the date the objection is made, including the date(s) such shares were acquired; (v) a statement of objections to any matters before the Court, the grounds therefor, as well as all documents or writings such Current Compass Stockholder desires the Court to consider; and (vi) the identities of any witnesses such Current Compass Stockholder plans on calling at the Settlement Hearing, along with a summary description of their expected testimony. Any objector who does not timely file and serve a notice of intention to appear in accordance with this paragraph shall be foreclosed from raising any objection to the Settlement and shall not be permitted to appear at the Settlement Hearing, except for good cause shown.

IF YOU MAKE A WRITTEN OBJECTION, IT MUST BE RECEIVED BY THE CLERK OF THE COURT NO LATER THAN January 30, 2026. The Clerk’s address is:

Clerk of the Court,
U.S. District Court for the District of Kansas
401 N. Market
Wichita, KS 67202

YOU ALSO MUST DELIVER COPIES OF THE MATERIALS TO PLAINTIFFS’ COUNSEL AND DEFENDANTS’ COUNSEL SO THEY ARE RECEIVED NO LATER THAN January 30, 2026. Counsel’s addresses are:

Counsel for Plaintiffs:

THE BROWN LAW FIRM, P.C.	GLANCY PRONGAY & MURRAY LLP
Timothy Brown	Benjamin I. Sachs-Michaels
767 Third Avenue, Suite 2501	745 Fifth Avenue, Fifth Floor
New York, NY 10017	New York, NY 10151

Counsel for Defendants:

SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
Jay B. Kasner
Susan L. Saltzstein
One Manhattan West
New York, NY 10001

An objector may file an objection on his, her, or its own or through an attorney hired at his, her, or its own expense. If an objector hires an attorney to represent him, her, or it for the purposes of making such objection, the attorney must serve (either by hand delivery or by first-class mail) a notice of appearance on the counsel listed above and file such notice with the Court no later than twenty-one (21) days before the Settlement Hearing. Any Compass stockholder who does not timely file and serve a written objection complying with the above terms shall be deemed to have waived, and shall be foreclosed from raising, any objection to the Settlement, and any untimely objection shall be barred.

Any objector who files and serves a timely, written objection in accordance with the instructions above, may appear at the Settlement Hearing either in person or through counsel retained at the objector’s expense. Objectors need not attend the Settlement Hearing, however, in order to have their objections considered by the Court.

If you are a Current Compass Stockholder and do not take steps to appear in this action and object to the proposed Settlement, you will be bound by the Judgment of the Court and will forever be barred from raising an objection to the settlement in the Actions and from pursuing any of the Released Claims.

CURRENT COMPASS STOCKHOLDERS AS OF OCTOBER 24, 2025 WHO HAVE NO OBJECTION TO THE SETTLEMENT DO NOT NEED TO APPEAR AT THE SETTLEMENT HEARING OR TAKE ANY OTHER ACTION.

Interim Stay and Injunction

Pending the Court’s determination as to final approval of the Settlement, Plaintiffs and Current Compass Stockholders are barred and enjoined from commencing, prosecuting, instigating, or in any way participating in the commencement or prosecution of any derivative action asserting any Released Claims against any of the Released Persons.

Scope of the Notice

This Notice is a summary description of the Actions, the complaints, the terms of the Settlement, and the Settlement Hearing. For full details of the matters discussed in this summary, please see the full Stipulation and its exhibits posted on the Investor Relations portion of the Company’s website, https://investors.compassminerals.com/investors-relations/overview/default.‌aspx, contact Plaintiffs’ Counsel as set forth below, or inspect the full Stipulation and its exhibits filed with the Clerk of the Court.

You may obtain further information by contacting Plaintiffs’ Counsel at: Timothy Brown, The Brown Law Firm, P.C., 767 Third Avenue, Suite 2501, New York, NY 10017, Telephone: (516) 922-5427, E-mail: [email protected]; or Benjamin I. Sachs-Michaels, Glancy Prongay & Murray LLP, 745 Fifth Avenue, Fifth Floor, New York, NY 10151 Telephone: (212) 935-7400, E-mail: [email protected]. Please Do Not Call the Court or Defendants with Questions About the Settlement.

Use of Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, those regarding: (i) the Stipulation resolving the derivative actions; (ii) the ability to secure final approval of the proposed Settlement and to satisfy all conditions of the proposed Settlement; and (iii) other statements that are not historical facts, constitute forward looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including, without limitation, risks and uncertainties related to: (a) the Stipulation not having the expected impact, including resolving the derivative actions; (b) the proposed settlement requiring more activity or expense than expected; (c) the defendants’ ability to overcome any objections or appeals regarding the proposed settlement; and (d) satisfactory resolution of any future litigation or other disagreements with others. Further information on potential factors that could cause actual results to differ materially from those in the forward-looking statements are contained in the Company’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere in such filings and reports, including our most recent annual report on Form 10-K for the period ended Sept. 30, 2025, and future filings and reports by the Company. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, the Company disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.

Investor Contact
[email protected]

Media Contact
[email protected]

December 23, 2025 4:38 pm

Amplify Energy Announces Closing of East Texas Divestiture

HOUSTON, Dec. 23, 2025 (GLOBE NEWSWIRE) — Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) announced today that it closed the previously announced transaction to sell its interests in East Texas for a contract price of $122.0 million, subject to customary post-closing adjustments.

The previously announced divestiture of the Company’s Oklahoma assets is still expected to close by the end of 2025.

About Amplify Energy

Amplify Energy Corp. is an independent oil company engaged in the acquisition, development, exploitation and production of oil. Amplify’s operations are focused in Oklahoma, Beta (Pacific Offshore Continental Shelf) and Bairoil (Rockies). For more information, visit www.amplifyenergy.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included in this press release that address activities, events or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. Terminology such as “may,” “will,” “would,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “outlook,” “continue,” the negative of such terms or other comparable terminology are intended to identify forward-looking statements. These statements include, but are not limited to, statements about the anticipated divestiture of Amplify’s assets in Oklahoma. These statements address activities, events or developments that we expect or anticipate will or may occur in the future, including things such as projections of results of operations, plans for growth, goals, future capital expenditures, competitive strengths, references to future intentions and other such references. These forward-looking statements involve risks and uncertainties and other factors that could cause the Company’s actual results or financial condition to differ materially from those expressed or implied by forward-looking statements. These include risks and uncertainties relating to, among other things: the ability to complete the potential sale of the Company’s assets in Oklahoma on favorable terms, or at all; the Company’s evaluation and implementation of strategic alternatives; risks related to the redetermination of the borrowing base under the Company’s revolving credit facility; the Company’s ability to satisfy debt obligations; the Company’s need to make accretive acquisitions or substantial capital expenditures to maintain its declining asset base, including the existence of unanticipated liabilities or problems relating to acquired or divested business or properties; volatility in the prices for oil, natural gas and NGLs; the Company’s ability to access funds on acceptable terms, if at all, because of the terms and conditions governing the Company’s indebtedness, including financial covenants; general political and economic conditions, globally and in the jurisdictions in which we operate, including the Russian invasion of Ukraine, and ongoing conflicts in the Middle East, trade wars and the potential destabilizing effect such conflicts may pose for the global oil and natural gas markets; expectations regarding general economic conditions, including inflation; and the impact of local, state and federal governmental regulations, including those related to climate change and hydraulic fracturing, and potential changes in these regulations. Please read the Company’s filings with the SEC, including “Risk Factors” in the Company’s Annual Report on Form 10-K, and if applicable, the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, which are available on the Company’s Investor Relations website at https://www.amplifyenergy.com/investor-relations/sec-filings/default.aspx or on the SEC’s website at http://www.sec.gov, for a discussion of risks and uncertainties that could cause actual results to differ from those in such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements in this press release are qualified in their entirety by these cautionary statements. Except as required by law, the Company undertakes no obligation and does not intend to update or revise any forward-looking statements, whether as a result of new information, future results or otherwise.

Contacts

Jim Frew — President and Chief Financial Officer
(832) 219-9044
[email protected]

Michael Jordan — Vice President, Finance and Treasury
(832) 219-9051
[email protected]

December 23, 2025 4:34 pm

StubHub Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 23, 2026 to Discuss Your Rights – STUB

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in StubHub Holdings, Inc. (“StubHub Holdings, Inc.” or the “Company”) (NYSE: STUB) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of StubHub Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired StubHub common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s September 2025 initial public offering. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/stubhub-holdings-inc-lawsuit-submission-form?prid=181248&wire=3

STUB investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company was experiencing changes in the timing of payments to vendors; (2) those changes had a significant adverse impact on free cash flow, including trailing 12 months free cash flow; (3) as a result, the Company’s free cash flow reports were materially misleading; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in StubHub Holdings, Inc. during the relevant time frame, you have until January 23, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

December 23, 2025 4:34 pm

Primo Brands Corporation / Primo Water Corporation Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – PRMB

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Primo Brands Corporation / Primo Water Corporation (“Primo Brands Corporation / Primo Water Corporation” or the “Company”) (NYSE: PRMB) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Primo Brands Corporation / Primo Water Corporation investors who were adversely affected by alleged securities fraud between June 17, 2024 and November 6, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/primo-brands-corporation-primo-water-corporation-lawsuit-submission-form?prid=181246&wire=3

PRMB investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that the merger integration between Primo Water and BlueTriton Brands was tracking poorly due to, among other things, technology and service issues. Moreover—and contrary to defendants’ statements assuring investors that the execution was “flawless”—Primo Brands was having major supply disruptions which would negatively impact customers and thus Primo Brands’ financial results.

WHAT’S NEXT? If you suffered a loss in Primo Brands Corporation / Primo Water Corporation during the relevant time frame, you have until January 12, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

December 23, 2025 4:34 pm

Investors who lost money on DeFi Technologies(DEFT) should contact Levi & Korsinsky about pending Class Action – DEFT

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in DeFi Technologies (“DeFi Technologies” or the “Company”) (NASDAQ: DEFT) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DeFi Technologies investors who were adversely affected by alleged securities fraud between May 12, 2025 and November 14, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/defi-technologies-lawsuit-submission-form?prid=181249&wire=3

DEFT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) DeFi Technologies was facing delays in executing its DeFi arbitrage strategy, which at all relevant times was a key revenue driver for the Company; (ii) DeFi Technologies had understated the extent of competition it faced from other digital asset treasury companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (iv) accordingly, defendants had downplayed the true scope and severity of the negative impact that the foregoing issues were having on DeFi Technologies’ business and financial results; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in DeFi Technologies during the relevant time frame, you have until January 30, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

December 23, 2025 4:33 pm

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

PR Newswire

Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025

CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year ended September 30, 2025.

“2025 was a pivotal year for Citius as we successfully launched LYMPHIR following its FDA approval, marking the first new systemic therapy for cutaneous T-cell lymphoma (CTCL) patients since 2018. This milestone reflects our ability to execute and our commitment to delivering impactful treatments for patients with limited options,” said Leonard Mazur, Chairman and CEO of Citius Pharma. “With LYMPHIR commercially available as of December 2025, we are focused on its successful launch and adoption in 2026, with even greater opportunities ahead to drive value for patients and shareholders. We are actively engaging with the FDA to advance Mino-Lok, exploring additional indications and markets for LYMPHIR, and working diligently to strengthen our financial and operational foundation to support sustained growth. We look forward to reporting on our continued progress in the coming months.”

Fiscal Year 2025 Business Highlights and Subsequent Developments

Citius Pharma subsidiary, Citius Oncology (Nasdaq: CTOR), launched LYMPHIR™ (denileukin diftitox-cxdl), a novel IL-2 receptor-directed immunotherapy, in the U.S. in December 2025 for the treatment of adult patients with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy;
Citius Pharma drove commercial preparations for LYMPHIR’s launch through its shared management services agreement with Citius Oncology:
- Executed service agreements with the three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR throughout the U.S.;
- Secured access to LYMPHIR in 19 international markets through regional distribution partners via named patient programs (NPPs), which allows access to LYMPHIR where permitted by local law without constituting commercial approval outside the U.S.;
- Ensured production and sufficient supply of LYMPHIR for up to 18 months of estimated commercial demand;
- Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines and compendia with a Category 2A recommendation, and a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) to aid in obtaining coverage and reimbursement;
- Partnered to deploy an AI-powered sales and marketing platform to enhance commercial targeting, real-time field execution, and provider engagement; and,
- Contracted with a leading provider of global commercialization services to supply medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, and channel management services;
Raised approximately $61 million in gross proceeds from capital raises:
- Citius Pharma closed $25 million in gross proceeds from strategic financings during and after the fiscal year end; and,
- Citius Oncology closed $36 million in gross proceeds from strategic financings during and after the fiscal year end; and,
Continued to engage with the FDA on the paths forward for Mino-Lok and Halo-Lido.

Fiscal Year 2025 Financial Highlights

Cash and cash equivalents of $4.3 million as of September 30, 2025;
Citius Pharma did not report revenues for the year;
R&D expenses were $9.2 million for the full year ended September 30, 2025, compared to $11.9 million for the full year ended September 30, 2024;
G&A expenses were $18.5 million for the full year ended September 30, 2025, compared to $18.2 million for the full year ended September 30, 2024;
Stock-based compensation expense was $10.8 million for the full year ended September 30, 2025, compared to $11.8 million for the full year ended September 30, 2024; and,
Net loss was $39.7 million, or ($3.38) per share for the fiscal year ended September 30, 2025 compared to a net loss of $40.2 million, or ($5.97) per share for the full year ended September 30, 2024.

About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.

About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 78% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma’s late-stage pipeline also includes Mino-Lok^®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma and Citius Oncology. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “plan,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to maintain Nasdaq’s continued listing standards; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; as well as other risks described in our Securities and Exchange Commission (“SEC”) filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC’s website at www.sec.gov, including in Citius Oncology’s Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Contact:
Ilanit Allen
[email protected]
908-967-6677 x113

Media Contact:
STiR-communications
Greg Salsburg
[email protected]

— Financial Tables Follow –

CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2025 AND 2024

	2025		2024
ASSETS
Current Assets:
Cash and cash equivalents	$	4,252,290	$	3,251,880
Inventory		22,286,693		8,268,766
Prepaid expenses		1,395,490		2,700,000
Total Current Assets		27,934,473		14,220,646

Operating lease right-of-use asset, net		818,694		246,247

Other Assets:
Deposits		38,062		38,062
In-process research and development		92,800,000		92,800,000
Goodwill		9,346,796		9,346,796
Total Other Assets		102,184,858		102,184,858

Total Assets	$	130,938,025	$	116,651,751

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	13,693,692	$	4,927,211
License payable		22,650,000		28,400,000
Accrued expenses		4,190,253		17,027
Accrued compensation		3,292,447		2,229,018
Note payable		1,000,000		—
Operating lease liability		88,348		241,547
Total Current Liabilities		44,914,740		35,814,803

Deferred tax liability		7,770,760		6,713,800
Operating lease liability – non current		724,925		21,318
Total Liabilities		53,410,425		42,549,921

Commitments and Contingencies

Stockholders’ Equity:
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding		—		—
Common stock – $0.001 par value; 250,000,000 and 16,000,000 shares authorized at September 30, 2025 and 2024, respectively; 18,067,744 and 7,247,243 shares issued and outstanding at September 30, 2025 and 2024, respectively		18,068		7,247
Additional paid-in capital		306,336,239		271,440,421
Accumulated deficit		(238,804,129)		(201,370,218)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity		67,550,178		70,077,450
Non-controlling interest		9,977,422		4,024,380
Total Equity		77,527,600		74,101,830

Total Liabilities and Equity	$	130,938,025	$	116,651,751

CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2025 AND 2024

	2025		2024
Revenues	$	—	$	—

Operating Expenses:
Research and development		9,156,474		11,906,601
General and administrative		18,532,843		18,249,402
Stock-based compensation – general and administrative		10,836,291		11,839,678
Total Operating Expenses		38,525,608		41,995,681

Operating Loss		(38,525,608)		(41,995,681)

Other Income (Expense):
Interest income		110,081		758,000
Interest expense		(267,782)		—
Gain on sale of New Jersey net operating losses		—		2,387,842
Total Other Income (Expense), Net		(157,701)		3,145,842

Loss before Income Taxes		(38,683,309)		(38,849,839)
Income tax expense		1,056,960		576,000

Net Loss		(39,740,269)		(39,425,839)
Net loss attributable to non-controlling interest		2,306,358		287,000
Deemed dividend on warrant extension		—		(1,047,312)

Net Loss Applicable to Common Stockholders	$	(37,433,911)		(40,186,151)

Net Loss Per Share Applicable to Common Stockholders – Basic and Diluted	$	(3.38)		(5.97)

Weighted Average Common Shares Outstanding
Basic and diluted		11,065,225		6,726,999

CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2025 AND 2024

	2025		2024
Cash Flows From Operating Activities:
Net loss	$	(39,740,269)	$	(39,425,839)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		10,836,291		11,839,678
Issuance of common stock for services		26,600		284,176
Amortization of operating lease right-of-use asset		214,250		208,179
Depreciation		—		1,432
Deferred income tax expense		1,056,960		576,000
Changes in operating assets and liabilities:
Inventory		(12,649,207)		(2,133,871)
Prepaid expenses		(64,210)		(945,389)
Accounts payable		8,766,481		1,999,877
Accrued expenses		4,173,226		(459,273)
Accrued compensation		1,063,429		72,035
Operating lease liability		(236,289)		(218,380)
Net Cash Used In Operating Activities		(26,552,738)		(28,201,375)
Cash Flows From Investing Activities:
License payment		(5,750,000)		(5,000,000)
Net Cash Used In Investing Activities		(5,750,000)		(5,000,000)

Cash Flows From Financing Activities:
Proceeds from note payable and advance from employee		1,300,000		—
Repayment of advance from employee		(300,000)		—
Merger, net		—		(3,831,357)
Net proceeds from common stock offerings		32,303,148		13,803,684
Net Cash Provided By Financing Activities		33,303,148		9,972,327

Net Change in Cash and Cash Equivalents		1,000,410		(23,229,048)
Cash and Cash Equivalents – Beginning of Year		3,251,880		26,480,928
Cash and Cash Equivalents – End of Year	$	4,252,290	$	3,251,880

Supplemental Disclosures of Cash Flow Information and Non-cash Activities:

IPR&D Milestones included in License Payable	$	—	$	28,400,000
Net Prepaid Manufacturing transferred to Inventory	$	1,368,720	$	6,134,895
Operating lease right-of-use asset and liability recorded	$	786,697	$	—
Interest paid	$	187,389	$	—

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update-302648899.html

SOURCE Citius Pharmaceuticals, Inc.

December 23, 2025 4:33 pm

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

PR Newswire

Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025

Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct offering on December 10, 2025, to strengthen cash position and support continued commercialization of LYMPHIR

CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ — Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today reported financial results for the fiscal year ended September 30, 2025, and provided a business update.

“2025 was a landmark year for Citius Oncology. With the U.S. commercial launch of LYMPHIR now underway, we have shifted from a pre-revenue to a revenue generating company,” said Leonard Mazur, Chairman and CEO of Citius Oncology and parent company Citius Pharmaceuticals. “Our focus now is on driving adoption, delivering value to patients, and realizing the full commercial potential of our first‑in‑class therapy. We intend to leverage our advanced AI-driven analytics to refine targeting, optimize field execution, and maximize commercial efficiency. In parallel, we have also begun laying the groundwork for international access with key distribution partners spanning 19 markets in Southern Europe and the Middle East via Named Patient Programs. These foundational efforts position us to scale and deliver sustained value to patients and shareholders alike.”

Fiscal Year 2025 Business Highlights and Subsequent Developments

Launched LYMPHIR™ (denileukin diftitox-cxdl), a novel IL‑2 receptor-directed immunotherapy, in the U.S. in December 2025 for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T‑cell lymphoma (CTCL) after at least one prior systemic therapy;
Executed service agreements with the three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR to healthcare organizations, including major medical centers and specialized hospitals treating oncology patients, community oncology practices, and infusion centers throughout the U.S.;
Secured access to LYMPHIR in 19 international markets through regional distribution partners via Named Patient Programs (NPPs), marking the first step in the Company’s global access strategy; NPPs allow access to LYMPHIR where permitted by local law without constituting commercial approval outside the U.S.;
Announced a collaboration with Verix to deploy its Tovana AI-powered platform to enhance commercial targeting, real-time field execution, and provider engagement in support of LYMPHIR’s U.S. commercialization and adoption; and,
Announced promising preliminary results of an investigator-initiated Phase I clinical trial of pembrolizumab and LYMPHIR™ in cancer patients with recurrent solid tumors.

Fiscal Full Year 2025 Financial Highlights

Cash and cash equivalents of $3.9 million as of September 30, 2025;
Closed $36 million in gross proceeds from strategic financings during and after the fiscal year end:

Completed an $18 million (gross proceeds) concurrent registered direct offering and private placement on December 10, 2025;
Completed a $9 million (gross proceeds) concurrent registered direct offering and private placement on September 10, 2025; and,
Completed a $9 million (gross proceeds) public offering on July 17, 2025.

Received $1 million from Citius Pharma as a note payable;
R&D expenses were $6.4 million for the full year ended September 30, 2025, compared to $4.9 million for the full year ended September 30, 2024;
G&A expenses were $8.8 million for the full year ended September 30, 2025, compared to $8.1 million for the full year ended September 30, 2024;
Stock-based compensation expense was $8.3 million for the full year ended September 30, 2025, compared to $7.5 million for the full year ended September 30, 2024; and,
Net loss was $24.8 million, or ($0.34) per share for the fiscal year ended September 30, 2025 compared to a net loss of $21.1 million, or ($0.31) per share for the full year ended September 30, 2024.

About Citius Oncology, Inc.

Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 78% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma’s late-stage pipeline also includes Mino-Lok^®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “plan,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to maintain Nasdaq’s continued listing standards; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission (“SEC”) filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC’s website at www.sec.gov, including in Citius Oncology’s Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Contact:
Ilanit Allen
[email protected]
908-967-6677 x113

Media Contact:
STiR-communications
Greg Salsburg
[email protected]

— Financial Tables Follow –

CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2025 AND 2024
	2025		2024
Current Assets:
Cash and cash equivalents	$	3,924,908	$	112
Inventory		22,286,693		8,268,766
Prepaid expenses		1,331,280		2,700,000
Total Current Assets		27,542,881		10,968,878

Other Assets:
In-process research and development		73,400,000		73,400,000
Total Other Assets		73,400,000		73,400,000

Total Assets	$	100,942,881	$	84,368,878
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	13,234,684	$	3,711,622
License payable		22,650,000		28,400,000
Accrued expenses		4,093,124		—
Due to related party		9,513,771		588,806
Total Current Liabilities		49,491,579		32,700,429

Deferred tax liability		2,784,960		1,728,000
Note payable to related party		3,800,111		3,800,111
Total Liabilities		56,076,650		38,228,540
Stockholders’ Equity:
Preferred stock – $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding		—		—
Common stock – $0.0001 par value; 400,000,000 and 100,000,000 shares authorized at September 30, 2025 and 2024, respectively; 83,513,442 and 71,552,402 shares issued and outstanding at September 30, 2025 and 2024, respectively		8,351		7,155
Additional paid-in capital		108,897,836		85,411,771
Accumulated deficit		(64,039,956)		(39,278,587)
Total Stockholders’ Equity		44,866,231		46,140,339
Total Liabilities and Stockholders’ Equity	$	100,942,881	$	84,368,878

CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2025 AND 2024
	2025		2024
Revenues	$	—	$	—
Operating Expenses:
Research and development		6,418,334		4,925,001
General and administrative		8,783,997		8,148,929
Stock-based compensation – general and administrative		8,320,419		7,498,817
Total Operating Expenses		23,522,750		20,572,747

Operating loss		(23,522,750)		(20,572,747)

Other Income (Expense)
Interest income		36,373		—
Interest expense		(218,032)		—
Total Other Income (Expense), Net		(181,659)		—

Loss before Income Taxes		(23,704,409)		(20,572,747)
Income tax expense		1,056,960		576,000

Net Loss	$	(24,761,369)	$	(21,148,747)

Net Loss Per Share – Basic and Diluted	$	(0.34)	$	(0.31)

Weighted Average Common Shares Outstanding – Basic and Diluted		73,267,969		68,053,607

CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2025 AND 2024
	2025		2024
Cash Flows From Operating Activities:
Net loss	$	(24,761,369)	$	(21,148,747)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock-based compensation expense		8,320,419		7,498,817
Deferred income tax expense		1,056,960		576,000
Changes in operating assets and liabilities:
Inventory		(12,649,207)		(2,133,871)
Prepaid expenses		–		(1,100,000)
Accounts payable		9,523,062		2,422,577
Accrued expenses		4,093,124		(259,071)
Due to related party		8,924,965		14,270,648
Net Cash (Used in) Provided By Operating Activities		(5,492,046)		126,353

Cash Flows From Investing Activities:
License payments		(5,750,000)		(5,000,000)
Net Cash Used In Investing Activities		(5,750,000)		(5,000,000)

Cash Flows From Financing Activities:
Net proceeds from issuance of common stock		15,166,842		–
Cash contributed by parent		–		3,827,944
Merger, net		–		(2,754,296)
Proceeds from issuance of note payable to related party		–		3,800,111
Net Cash Provided By Financing Activities		15,166,842		4,873,759
Net Change in Cash and Cash Equivalents		3,924,796		112
Cash and Cash Equivalents – Beginning of Year		112		–
Cash and Cash Equivalents – End of Year	$	3,924,908	$	112
Supplemental Disclosures of Cash Flow Information and Non-cash Activities:
IPR&D Milestones included in License Payable	$	–	$	28,400,000
Capital Contribution of due to related party by parent	$	–	$	33,180,961
Net Prepaid Manufacturing transferred to Inventory	$	1,368,720	$	6,134,895
Interest Paid	$	187,389	$	–

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-year-2025-financial-results-and-provides-business-update-302648892.html

SOURCE Citius Oncology, Inc.

December 23, 2025 4:33 pm

Simmons First National Corporation Announces Fourth Quarter 2025 Earnings Release Date and Conference Call

PR Newswire

PINE BLUFF, Ark., Dec. 23, 2025 /PRNewswire/ — Simmons First National Corporation (NASDAQ: SFNC) today announced it is scheduled to release fourth quarter 2025 earnings after the market closing on Tuesday, January 20, 2026. Management will conduct a live conference call to review this information beginning at 7:30 a.m. Central Time on Wednesday, January 21. Interested parties can listen to the call by dialing toll-free 1-844-481-2779 (North America only) and asking for the Simmons First National Corporation conference call, conference ID 10205234. In addition, the call will be available live or in recorded version on our website at simmonsbank.com under the “Investor Relations” tab. The recorded version will be available for at least 60 days following the date of the call.

Simmons First National Corporation
Simmons First National Corporation (NASDAQ: SFNC) is a Mid-South based financial holding company that has paid cash dividends to its shareholders for 116 consecutive years. Its principal subsidiary, Simmons Bank, operates more than 220 branches in Arkansas, Kansas, Missouri, Oklahoma, Tennessee and Texas. Founded in 1903, Simmons Bank offers comprehensive financial solutions delivered with a client-centric approach. Recently, Simmons Bank was recognized by Newsweek as one of America’s Best Regional Banks and Credit Unions 2026 and by Forbes as one of America’s Best-In-State Companies 2026. In 2025, Simmons Bank was recognized by Newsweek as one of America’s Greatest Workplaces 2025 in Arkansas and one of America’s Best Regional Banks 2025, and by U.S. News & World Report as one of the 2024-2025 Best Companies to Work For in the South. Additional information about Simmons Bank can be found on our website at simmonsbank.com, by following @Simmons_Bank on X or by visiting our newsroom.

View original content to download multimedia:https://www.prnewswire.com/news-releases/simmons-first-national-corporation-announces-fourth-quarter-2025-earnings-release-date-and-conference-call-302648945.html

SOURCE Simmons First National Corporation

December 23, 2025 4:33 pm

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. Lawsuit – TLX

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. (“Telix Pharmaceuticals Ltd.” or the “Company”) (NASDAQ: TLX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/telix-pharmaceuticals-ltd-lawsuit-submission-form?prid=181245&wire=3

TLX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) defendants materially overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants’ statements about Telix’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHAT’S NEXT? If you suffered a loss in Telix Pharmaceuticals Ltd. during the relevant time frame, you have until January 9, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

December 23, 2025 4:33 pm

Multi Ways Holdings Reports 88% Revenue Growth in First Half 2025, Provides Corporate Updates

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) — Multi Ways Holdings Limited (“Multi Ways” or the “Company”) (NYSE American: MWG), a leading supplier of a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region, today announces first half 2025 unaudited financial results and provides corporate updates.

Management Commentary

Mr. James Lim, Chairman and Chief Executive Officer of Multi Ways, is pleased to report that, “In the first half of 2025, despite a challenging and rapidly evolving business environment, the Group achieved a year-on-year increase in revenue. This growth was primarily driven by the strong performance of our equipment sales segment, reflecting the market’s confidence in our product offerings and our ability to capture new opportunities even under difficult conditions.

“However, our gross profit margin experienced a decline during the period. This outcome was influenced by a combination of factors, including heightened competitive pressures, rising input costs, and sales mix associated with the higher contribution from lower-margin equipment products. We are addressing these challenges through continued cost-management initiatives, operational efficiencies, and ongoing optimisation of our product portfolio.

“Looking ahead to 2026, we are optimistic about our business prospects given several recently announced major infrastructure projects commencing construction next year. These include the ongoing expansion of Changi Airport Terminal 5 and the Marina Bay Sands integrated resort, along with strong government focus on public housing, high-specification industrial buildings, and educational and healthcare facilities. Additionally, large-scale infrastructure projects such as the Jurong Region Line (JRL), the Cross Island Line (CRL), and the Jurong Island Hydrogen-Compatible Power Plant continue to progress.

“Multi Ways remains committed to strengthening our core capabilities, enhancing profitability, and delivering sustainable value for our shareholders. While external uncertainties may persist, we believe our strategic direction and disciplined execution position us well for long-term growth,” concluded Mr. Lim.

First Half 2025 Financial Highlights

For the six months ended June 30, 2025, our net revenue increased significantly by 87.65% to $26.44 million, compared to $14.09 million for the six months ended June 30, 2024. The increase in net revenue was largely due to several factors, including:

Strong equipment sales boosted by few local ongoing major infrastructure projects
Sales orders locked-in last year which translated into revenue in 1^st half 2025.
Aggressive & proactive marketing strategy to entice potential customers
Gross profit was approximately $6.63 million, with 25.08% profit margin, for the first six months of 2025, compared with gross profit of $4.66 million, with 33.07% profit margin for the first six months of 2024.
Net income was approximately $0.90 million for the first six months of 2025, compared with a net income of $0.08 million for the first six months of 2024. Net Income increased substantially by 1,025% to $0.82 million.

Cash Flows Summary

Cash and cash equivalents were approximately $1.14 million as of June 30, 2025, compared to approximately $3.66 million as of June 30, 2024.
Cash generated from operating activities for the six months ended June 30, 2025, was approximately $5.39 million, compared to cash used in operating activities of approximately $8.03 million for the six months ended June 30, 2024.
Cash used in investing activities for the six months ended June 30, 2025, was $0.20 million, compared to cash used in investing activities of $0.18 million for the six months ended June 30, 2024.
Cash used in financing activities for the six months ended June 30, 2025, was approximately $7.14 million, compared to cash generated from financing activities of approximately $5.22 million for the six months ended June 30, 2024.

About Multi Ways Holdings Limited

Multi Ways Holdings supplies a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region. With more than two decades of experience in the sales and rental of heavy construction equipment business, the Company is widely established as a reliable supplier of new and used heavy construction equipment to customers from Singapore, Australia, UAE, Maldives, Indonesia, and the Philippines. With our wide variety of heavy construction equipment in our inventory and complementary equipment refurbishment and cleaning services, Multi Ways is well-positioned to serve customers as a one-stop shop. For more information, visit www.multiwaysholdings.com.

Safe Harbor Statement

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Investor Relations Contact:

Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: [email protected]